It is noteworthy that the high affinity of the CLDN18-ARHGAP26 fusion protein for the cell membrane, as well as its exclusive expression in gastric cancer cells provide new opportunities for targeted therapies [16]. This evidence concerns the gene ARHGAP26 and gastric cancer.